{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:03:23Z","timestamp":1793664203998,"version":"4.5.1"},"reference-count":254,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,8,8]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Immuno-oncology has revolutionized cancer treatment by mobilizing the immune system to eliminate tumors. Although immune checkpoint inhibitors and T cell therapies have mediated durable responses in hematologic malignancies and select solid tumors, most patients still relapse or fail to respond. To overcome these limitations, novel, next-generation immune constructs, including bispecific-cell therapy combinations, armored cells, tethered cytokines, immune-stimulatory antibody conjugates, and in vivo gene editing, are being developed to enhance specificity, persistence, and immune activation. This Society for Immunotherapy of Cancer roadmap highlights emerging technologies that integrate, redirect, or potentiate immune response. We examine advances in construct design, strategies for clinical translation, and opportunities for combinatorial approaches. By addressing translational barriers and real-world challenges, we outline how innovative engineering can unlock a new era of safe, durable, and accessible immunotherapies. Realizing this potential will require coordinated efforts from researchers, clinicians, industry leaders, and policymakers to deliver curative outcomes to patients worldwide.<\/jats:p>","DOI":"10.1136\/jitc-2025-011761","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T02:12:48Z","timestamp":1756174368000},"page":"e011761","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Constructing the cure: engineering the next wave of antibody and cellular immune therapies"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04460456","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05091528","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05954143","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05514717","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05070247","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04420884","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06060613","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05470283","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01174121","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05573035","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05361174","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04426669","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03726515","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05057715","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04381741","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04539444","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05000450","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05007379","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04660929","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06224738","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04405778","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05164666","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Stefanie R","family":"Bailey","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1793-446X","authenticated-orcid":false,"given":"Eric","family":"Bartee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Health Sciences Center, University of New Mexico, Albuquerque, New Mexico, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle G","family":"Daniels","sequence":"additional","affiliation":[{"name":"Department of Genetics, Stanford School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R","family":"Heery","sequence":"additional","affiliation":[{"name":"Arcellx, Redwood City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8647-3911","authenticated-orcid":false,"given":"Pravin","family":"Kaumaya","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8787-7678","authenticated-orcid":false,"given":"Gregory B","family":"Lesinski","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy B","family":"Lowinger","sequence":"additional","affiliation":[{"name":"Mersana Therapeutics, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle H","family":"Nelson","sequence":"additional","affiliation":[{"name":"Aptevo Therapeutics, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P","family":"Rubinstein","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-4955","authenticated-orcid":false,"given":"Megen C","family":"Wittling","sequence":"additional","affiliation":[{"name":"Department of Surgery, Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrystal M","family":"Paulos","sequence":"additional","affiliation":[{"name":"Department of Surgery, Emory University, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8711-629X","authenticated-orcid":false,"suffix":"Jr","given":"Avery D","family":"Posey","sequence":"additional","affiliation":[{"name":"Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"2026052108402888000_13.8.e011761.1","first-page":"154","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop J"},{"key":"2026052108402888000_13.8.e011761.2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1490019"},{"key":"2026052108402888000_13.8.e011761.3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2769"},{"key":"2026052108402888000_13.8.e011761.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2026052108402888000_13.8.e011761.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"2026052108402888000_13.8.e011761.6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature New Biol"},{"key":"2026052108402888000_13.8.e011761.7","doi-asserted-by":"crossref","unstructured":"Alsaafeen BH , Ali BR , Elkord E . Resistance mechanisms to immune checkpoint inhibitors: updated insights. Mol Cancer 2025;24. doi:10.1186\/s12943-024-02212-7","DOI":"10.1186\/s12943-024-02212-7"},{"key":"2026052108402888000_13.8.e011761.8","doi-asserted-by":"crossref","unstructured":"Wang Z , Li P , Zeng X , et al . CAR-T therapy dilemma and innovative design strategies for next generation. Cell Death Dis 2025;16. doi:10.1038\/s41419-025-07454-x","DOI":"10.1038\/s41419-025-07454-x"},{"key":"2026052108402888000_13.8.e011761.9","doi-asserted-by":"crossref","unstructured":"Wittling MC , Cole AC , Brammer B , et al . Strategies for improving CAR T cell persistence in solid tumors. Cancers (Basel) 2024;16. doi:10.3390\/cancers16162858","DOI":"10.3390\/cancers16162858"},{"key":"2026052108402888000_13.8.e011761.10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.trecan.2024.05.007","article-title":"Future perspectives on engineered T cells for cancer","volume":"10","author":"Posey","year":"2024","journal-title":"Trends Cancer"},{"key":"2026052108402888000_13.8.e011761.11","doi-asserted-by":"crossref","unstructured":"Knochelmann HM , Smith AS , Dwyer CJ , et al . CAR T cells in solid tumors: blueprints for building effective therapies. Front Immunol 2018;9. doi:10.3389\/fimmu.2018.01740","DOI":"10.3389\/fimmu.2018.01740"},{"key":"2026052108402888000_13.8.e011761.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1835"},{"key":"2026052108402888000_13.8.e011761.13","doi-asserted-by":"crossref","unstructured":"Uslu U , Sun L , Castelli S , et al . The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion. Nat Commun 2024;15. doi:10.1038\/s41467-024-47692-9","DOI":"10.1038\/s41467-024-47692-9"},{"key":"2026052108402888000_13.8.e011761.14","doi-asserted-by":"crossref","unstructured":"Emens LA , Romero PJ , Anderson AC , et al . Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. J Immunother Cancer 2024;12. doi:10.1136\/jitc-2024-009063","DOI":"10.1136\/jitc-2024-009063"},{"key":"2026052108402888000_13.8.e011761.15","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1016\/j.sjbs.2021.06.044","article-title":"Traditional ancient Egyptian medicine: a review","volume":"28","author":"Metwaly","year":"2021","journal-title":"Saudi J Biol Sci"},{"key":"2026052108402888000_13.8.e011761.16","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00968-1"},{"key":"2026052108402888000_13.8.e011761.17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/ITT.S163924","article-title":"William Bradley Coley, MD, and the phenomenon of spontaneous regression","volume":"7","author":"Vernon","year":"2018","journal-title":"Immunotargets Ther"},{"key":"2026052108402888000_13.8.e011761.18","doi-asserted-by":"crossref","unstructured":"Larson C , Oronsky B , Reid TR . Commentary on oncolytic viruses: past, present, and future. J Immunother Cancer 2023;11. doi:10.1136\/jitc-2023-007905","DOI":"10.1136\/jitc-2023-007905"},{"key":"2026052108402888000_13.8.e011761.19","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat Cancer"},{"key":"2026052108402888000_13.8.e011761.20","doi-asserted-by":"crossref","unstructured":"Tojjari A , Saeed A , Singh M , et al . A comprehensive review on cancer vaccines and vaccine strategies in Hepatocellular carcinoma. Vaccines (Basel) 2023;11. doi:10.3390\/vaccines11081357","DOI":"10.3390\/vaccines11081357"},{"key":"2026052108402888000_13.8.e011761.21","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0224"},{"key":"2026052108402888000_13.8.e011761.22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3997"},{"key":"2026052108402888000_13.8.e011761.23","doi-asserted-by":"crossref","first-page":"826566","DOI":"10.3389\/fonc.2022.826566","article-title":"Preclinical studies of a novel human PD-1 B-cell peptide cancer vaccine PD1-Vaxx From BALB\/c mice to beagle dogs and to non-human primates (Cynomolgus monkeys)","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"2026052108402888000_13.8.e011761.24","doi-asserted-by":"crossref","unstructured":"Kaumaya PTP , Guo L , Overholser J , et al . Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab\/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. Oncoimmunology 2020;9. doi:10.1080\/2162402X.2020.1818437","DOI":"10.1080\/2162402X.2020.1818437"},{"key":"2026052108402888000_13.8.e011761.25","doi-asserted-by":"crossref","unstructured":"Richardson GE , Park JJ , Boyer MJ , et al . IMPRINTER: an open label, multicenter, dose escalation\/expansion, phase 1 study of imu-201 (pd1-vaxx). In: A B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults With Non-Small Cell Lung Cancer (IMU. 201.101). American Society of Clinical Oncology, 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.e21134"},{"key":"2026052108402888000_13.8.e011761.26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/jir.2017.0101","article-title":"IL-2 and beyond in cancer immunotherapy","volume":"38","author":"Wrangle","year":"2018","journal-title":"J Interferon Cytokine Res"},{"key":"2026052108402888000_13.8.e011761.27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510360033032"},{"key":"2026052108402888000_13.8.e011761.28","doi-asserted-by":"publisher","DOI":"10.1126\/science.3131876"},{"key":"2026052108402888000_13.8.e011761.29","doi-asserted-by":"crossref","unstructured":"Rosenberg SA . Interleukin 2 for patients with renal cancer. Nat Clin Pract Oncol 2007;4. doi:10.1038\/ncponc0926","DOI":"10.1038\/ncponc0926"},{"key":"2026052108402888000_13.8.e011761.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812223192527"},{"key":"2026052108402888000_13.8.e011761.31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood.V57.3.379.379","article-title":"Human T-lymphocyte growth factor: regulation of growth and function of T lymphocytes","volume":"57","author":"Ruscetti","year":"1981","journal-title":"Blood"},{"key":"2026052108402888000_13.8.e011761.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198512053132327"},{"key":"2026052108402888000_13.8.e011761.33","first-page":"5074s","article-title":"Immunotherapy and gene therapy of cancer","volume":"51","author":"Rosenberg","year":"1991","journal-title":"Cancer Res"},{"key":"2026052108402888000_13.8.e011761.34","doi-asserted-by":"publisher","DOI":"10.1126\/science.1122927"},{"key":"2026052108402888000_13.8.e011761.35","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","article-title":"IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy","volume":"583","author":"Zhou","year":"2020","journal-title":"Nature New Biol"},{"key":"2026052108402888000_13.8.e011761.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05192-0"},{"key":"2026052108402888000_13.8.e011761.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.04.004"},{"key":"2026052108402888000_13.8.e011761.38","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-311585"},{"key":"2026052108402888000_13.8.e011761.39","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30148-7"},{"key":"2026052108402888000_13.8.e011761.40","doi-asserted-by":"crossref","unstructured":"Kean LS , Blazar BR . Major breakthroughs in hematopoietic stem cell transplantation and future challenges in clinical implementation. J Clin Invest 2024;134. doi:10.1172\/JCI179944","DOI":"10.1172\/JCI179944"},{"key":"2026052108402888000_13.8.e011761.41","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2355"},{"key":"2026052108402888000_13.8.e011761.42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.240"},{"key":"2026052108402888000_13.8.e011761.43","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.174"},{"key":"2026052108402888000_13.8.e011761.44","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"2026052108402888000_13.8.e011761.45","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature New Biol"},{"key":"2026052108402888000_13.8.e011761.46","doi-asserted-by":"crossref","unstructured":"Mamdani H , Matosevic S , Khalid AB , et al . Immunotherapy in lung cancer: current landscape and future directions. Front Immunol 2022;13. doi:10.3389\/fimmu.2022.823618","DOI":"10.3389\/fimmu.2022.823618"},{"key":"2026052108402888000_13.8.e011761.47","doi-asserted-by":"crossref","unstructured":"Trojaniello C , Luke JJ , Ascierto PA . Therapeutic advancements across clinical stages in Melanoma, with a focus on targeted immunotherapy. Front Oncol 2021;11. doi:10.3389\/fonc.2021.670726","DOI":"10.3389\/fonc.2021.670726"},{"key":"2026052108402888000_13.8.e011761.48","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41571-020-0328-8","article-title":"Biology confirmed but biomarkers elusive in melanoma immunotherapy","volume":"17","author":"Luke","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2026052108402888000_13.8.e011761.49","doi-asserted-by":"crossref","unstructured":"Bicak M , Cimen Bozkus C , Bhardwaj N . Checkpoint therapy in cancer treatment: progress, challenges, and future directions. J Clin Invest 2024;134. doi:10.1172\/JCI184846","DOI":"10.1172\/JCI184846"},{"key":"2026052108402888000_13.8.e011761.50","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2026052108402888000_13.8.e011761.51","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711"},{"key":"2026052108402888000_13.8.e011761.52","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20721"},{"key":"2026052108402888000_13.8.e011761.53","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318279652e"},{"key":"2026052108402888000_13.8.e011761.54","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMc2300132","article-title":"Tumor-infiltrating lymphocyte therapy in advanced melanoma. reply","volume":"388","author":"Rohaan","year":"2023","journal-title":"N Engl J Med"},{"key":"2026052108402888000_13.8.e011761.55","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2643-3230.BCD-24-0124","article-title":"T cell-redirecting bispecific antibodies in multiple Myeloma: optimal dosing schedule and duration of treatment","volume":"5","author":"van de Donk","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"2026052108402888000_13.8.e011761.56","doi-asserted-by":"crossref","unstructured":"Allen C , Zeidan AM , Bewersdorf JP . BiTEs, DARTS, BiKEs and TriKEs-are antibody based therapies changing the future treatment of AML? Life (Basel) 2021;11. doi:10.3390\/life11060465","DOI":"10.3390\/life11060465"},{"key":"2026052108402888000_13.8.e011761.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006"},{"key":"2026052108402888000_13.8.e011761.58","doi-asserted-by":"crossref","unstructured":"Pavlick AC , Ariyan CE , Buchbinder EI , et al . Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. J Immunother Cancer 2023;11. doi:10.1136\/jitc-2023-006947","DOI":"10.1136\/jitc-2022-006624corr1"},{"key":"2026052108402888000_13.8.e011761.59","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/cncr.35063","article-title":"Phase 1\/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies","volume":"130","author":"Knisely","year":"2024","journal-title":"Cancer"},{"key":"2026052108402888000_13.8.e011761.60","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101414","article-title":"Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin\u2019s lymphoma","volume":"5","author":"Ma","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026052108402888000_13.8.e011761.61","doi-asserted-by":"crossref","unstructured":"Melero I , Tanos T , Bustamante M , et al . A first-in-human study of the fibroblast activation protein\u2013targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Sci Transl Med 2023;15. doi:10.1126\/scitranslmed.abp9229","DOI":"10.1126\/scitranslmed.abp9229"},{"key":"2026052108402888000_13.8.e011761.62","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1158\/2767-9764.CRC-24-0185","article-title":"Phase I study of simlukafusp alfa (FAP-IL2v) with or without atezolizumab in Japanese patients with advanced solid tumors","volume":"4","author":"Koyama","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2026052108402888000_13.8.e011761.63","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1158\/1078-0432.CCR-22-1379","article-title":"Monitoring therapeutic response to anti-FAP CAR T cells using [18F]AlF-FAPI-74","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026052108402888000_13.8.e011761.64","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2023023381","article-title":"CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy","volume":"143","author":"Sam","year":"2024","journal-title":"Blood"},{"key":"2026052108402888000_13.8.e011761.65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"2026052108402888000_13.8.e011761.66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2677"},{"key":"2026052108402888000_13.8.e011761.67","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03083-7"},{"key":"2026052108402888000_13.8.e011761.68","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00546-2"},{"key":"2026052108402888000_13.8.e011761.69","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2387"},{"key":"2026052108402888000_13.8.e011761.70","doi-asserted-by":"crossref","unstructured":"Sharma N , Atolagbe OT , Ge Z , et al . LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med 2021;218. doi:10.1084\/jem.20201811","DOI":"10.1084\/jem.20201811"},{"key":"2026052108402888000_13.8.e011761.71","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1245\/s10434-021-10111-0","article-title":"Pepinemab (Anti-SEMA4D) in combination with ipilimumab or nivolumab for patients with resectable pancreatic and colorectal cancer","volume":"28","author":"Rossi","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"2026052108402888000_13.8.e011761.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.05.001"},{"key":"2026052108402888000_13.8.e011761.73","unstructured":"Food U , Administration D . Bispecific antibodies: an area of research and clinical applications. 2023."},{"key":"2026052108402888000_13.8.e011761.74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.2098"},{"key":"2026052108402888000_13.8.e011761.75","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","article-title":"Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements","volume":"12","author":"Schram","year":"2022","journal-title":"Cancer Discov"},{"key":"2026052108402888000_13.8.e011761.76","doi-asserted-by":"crossref","unstructured":"Schram AM , Goto K , Kim D-W , et al . Efficacy and Safety of Zenocutuzumab, a HER2 x HER3 Bispecific Antibody, across Advanced NRG1 Fusion (NRG1+) Cancers. American Society of Clinical Oncology, 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.105"},{"key":"2026052108402888000_13.8.e011761.77","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026052108402888000_13.8.e011761.78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543776.2024.2423018","article-title":"Trispecific anti-CD3\/BCMA\/CD38 antibodies for multiple myeloma: a patent evaluation of US20240132615","volume":"35","author":"Bandala","year":"2025","journal-title":"Expert Opin Ther Pat"},{"key":"2026052108402888000_13.8.e011761.79","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"2026052108402888000_13.8.e011761.80","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00905-y"},{"key":"2026052108402888000_13.8.e011761.81","doi-asserted-by":"crossref","unstructured":"Ord\u00f3\u00f1ez-Reyes C , Garcia-Robledo JE , Chamorro DF , et al . Bispecific antibodies in cancer immunotherapy: a novel response to an old question. Pharmaceutics 2022;14. doi:10.3390\/pharmaceutics14061243","DOI":"10.3390\/pharmaceutics14061243"},{"key":"2026052108402888000_13.8.e011761.82","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01053-x","article-title":"Novel therapies emerging in oncology to target the TGF-\u03b2 pathway","volume":"14","author":"Kim","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026052108402888000_13.8.e011761.83","doi-asserted-by":"crossref","unstructured":"Stein MN , Zhang J , Kelly WK , et al . Preliminary Results from a Phase 1\/2 Study of Co-Stimulatory Bispecific PSMAxCD28 Antibody REGN5678 in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC). American Society of Clinical Oncology, 2023.","DOI":"10.1200\/JCO.2023.41.6_suppl.154"},{"key":"2026052108402888000_13.8.e011761.84","doi-asserted-by":"crossref","unstructured":"Linke R , Klein A , Seimetz D , eds. Catumaxomab: Clinical Development and Future Directions. Taylor & Francis: MAbs, 2010.","DOI":"10.4161\/mabs.2.2.11221"},{"key":"2026052108402888000_13.8.e011761.85","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1182\/blood-2022-167468","article-title":"Molecule, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"140","author":"Watts","year":"2022","journal-title":"Blood"},{"key":"2026052108402888000_13.8.e011761.86","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0984"},{"key":"2026052108402888000_13.8.e011761.87","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2024.5424","article-title":"Claudin 1, 4, 6 and 18 isoform 2 as targets for the treatment of cancer (Review)","volume":"54","author":"Katoh","year":"2024","journal-title":"Int J Mol Med"},{"key":"2026052108402888000_13.8.e011761.88","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00709-2"},{"key":"2026052108402888000_13.8.e011761.89","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00850-2"},{"key":"2026052108402888000_13.8.e011761.90","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1012501"},{"key":"2026052108402888000_13.8.e011761.91","doi-asserted-by":"crossref","unstructured":"Amouzegar A , Chelvanambi M , Filderman JN , et al . STING agonists as cancer therapeutics. Cancers (Basel) 2021;13. doi:10.3390\/cancers13112695","DOI":"10.3390\/cancers13112695"},{"key":"2026052108402888000_13.8.e011761.92","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1158\/2326-6066.CIR-21-0722","article-title":"Preclinical characterization and phase I study of an anti-HER2-TLR7 immune-stimulator antibody conjugate in patients with HER2+ malignancies","volume":"10","author":"Janku","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2026052108402888000_13.8.e011761.93","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/genedge.6.01.092","article-title":"StockWatch: like a Bolt from the blue, cancer drug developer nosedives: After lead candidate misses efficacy benchmark, Bolt Biotherapeutics halves its workforce, pivots pipeline, and upends C-suite","volume":"6","author":"Philippidis","year":"2024","journal-title":"GEN Edge"},{"key":"2026052108402888000_13.8.e011761.94","doi-asserted-by":"crossref","unstructured":"Malli Cetinbas N , Monnell T , Soomer-James J , et al . Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses. Nat Commun 2024;15. doi:10.1038\/s41467-024-49932-4","DOI":"10.1038\/s41467-024-49932-4"},{"key":"2026052108402888000_13.8.e011761.95","doi-asserted-by":"crossref","unstructured":"Bailey SR , Berger TR , Graham C , et al . Four challenges to CAR T cells breaking the glass ceiling. Eur J Immunol 2023;53. doi:10.1002\/eji.202250039","DOI":"10.1002\/eji.202250039"},{"key":"2026052108402888000_13.8.e011761.96","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4049\/jimmunol.138.3.989","article-title":"Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma","volume":"138","author":"Muul","year":"1987","journal-title":"J Immunol"},{"key":"2026052108402888000_13.8.e011761.97","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/s41591-025-03708-5","article-title":"Publisher Correction: Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial","volume":"31","author":"Lowery","year":"2025","journal-title":"Nat Med"},{"key":"2026052108402888000_13.8.e011761.98","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41571-023-00848-w","article-title":"Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma","volume":"21","author":"Klobuch","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026052108402888000_13.8.e011761.99","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3685"},{"key":"2026052108402888000_13.8.e011761.100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.06.015"},{"key":"2026052108402888000_13.8.e011761.101","doi-asserted-by":"crossref","unstructured":"Albarr\u00e1n Fern\u00e1ndez V , Ballest\u00edn Mart\u00ednez P , Stoltenborg Granh\u00f8j J , et al . Biomarkers for response to TIL therapy: a comprehensive review. J Immunother Cancer 2024;12. doi:10.1136\/jitc-2023-008640","DOI":"10.1136\/jitc-2023-008640"},{"key":"2026052108402888000_13.8.e011761.102","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/320232a0","article-title":"Transfer of specificity by murine \u03b1 and \u03b2 T-cell receptor genes","volume":"320","author":"Dembi\u0106","year":"1986","journal-title":"Nature New Biol"},{"key":"2026052108402888000_13.8.e011761.103","doi-asserted-by":"publisher","DOI":"10.1038\/ni1001-957"},{"key":"2026052108402888000_13.8.e011761.104","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.1.507"},{"key":"2026052108402888000_13.8.e011761.105","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(99)00155-X"},{"key":"2026052108402888000_13.8.e011761.106","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129003"},{"key":"2026052108402888000_13.8.e011761.107","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2537"},{"key":"2026052108402888000_13.8.e011761.108","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182829903"},{"key":"2026052108402888000_13.8.e011761.109","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1200\/JCO.2015.65.5142","article-title":"T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression","volume":"34","author":"Chapuis","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026052108402888000_13.8.e011761.110","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119662"},{"key":"2026052108402888000_13.8.e011761.111","doi-asserted-by":"crossref","unstructured":"Baulu E , Gardet C , Chuvin N , et al . TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv 2023;9. doi:10.1126\/sciadv.adf3700","DOI":"10.1126\/sciadv.adf3700"},{"key":"2026052108402888000_13.8.e011761.112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2026052108402888000_13.8.e011761.113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2026052108402888000_13.8.e011761.114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"2026052108402888000_13.8.e011761.115","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"2026052108402888000_13.8.e011761.116","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"2026052108402888000_13.8.e011761.117","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01564-7"},{"key":"2026052108402888000_13.8.e011761.118","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-201080","article-title":"Phase 1 study of anitocabtagene autoleucel for the treatment of patients with Relapsed and\/or Refractory Multiple Myeloma (RRMM): efficacy and safety with 34-month median follow-up","volume":"144","author":"Bishop","year":"2024","journal-title":"Blood"},{"key":"2026052108402888000_13.8.e011761.119","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-198499","article-title":"Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: preliminary results from the immagine-1 trial","volume":"144","author":"Freeman","year":"2024","journal-title":"Blood"},{"key":"2026052108402888000_13.8.e011761.120","doi-asserted-by":"crossref","unstructured":"Gong Z , Umoru G , Monge J , et al . Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study. Blood Cancer J 2024;14. doi:10.1038\/s41408-024-01023-9","DOI":"10.1038\/s41408-024-01023-9"},{"key":"2026052108402888000_13.8.e011761.121","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00832-4"},{"key":"2026052108402888000_13.8.e011761.122","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04489-4"},{"key":"2026052108402888000_13.8.e011761.123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610497"},{"key":"2026052108402888000_13.8.e011761.124","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8"},{"key":"2026052108402888000_13.8.e011761.125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210859"},{"key":"2026052108402888000_13.8.e011761.126","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41591-025-03513-0","article-title":"Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma","volume":"31","author":"Li","year":"2025","journal-title":"Nat Med"},{"key":"2026052108402888000_13.8.e011761.127","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/2326-6066.CIR-21-0536","article-title":"Superkine IL-2 and IL-33 armored CAR T cells reshape the tumor microenvironment and reduce growth of multiple solid tumors","volume":"10","author":"Brog","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2026052108402888000_13.8.e011761.128","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.07.005"},{"key":"2026052108402888000_13.8.e011761.129","doi-asserted-by":"crossref","unstructured":"Koneru M , Purdon TJ , Spriggs D , et al . IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology 2015;4. doi:10.4161\/2162402X.2014.994446","DOI":"10.4161\/2162402X.2014.994446"},{"key":"2026052108402888000_13.8.e011761.130","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0103"},{"key":"2026052108402888000_13.8.e011761.131","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1811"},{"key":"2026052108402888000_13.8.e011761.132","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.04.051"},{"key":"2026052108402888000_13.8.e011761.133","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.063"},{"key":"2026052108402888000_13.8.e011761.134","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.09.002"},{"key":"2026052108402888000_13.8.e011761.135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.003"},{"key":"2026052108402888000_13.8.e011761.136","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.016"},{"key":"2026052108402888000_13.8.e011761.137","doi-asserted-by":"crossref","unstructured":"Yoshikawa T , Ito Y , Wu Z , et al . Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. Cell Rep Med 2024;5. doi:10.1016\/j.xcrm.2024.101526","DOI":"10.1016\/j.xcrm.2024.101526"},{"key":"2026052108402888000_13.8.e011761.138","doi-asserted-by":"crossref","first-page":"8893","DOI":"10.2147\/CMAR.S260915","article-title":"EGLIF-CAR-T cells secreting PD-1 blocking antibodies significantly mediate the elimination of gastric cancer","volume":"12","author":"Zhou","year":"2020","journal-title":"Cancer Manag Res"},{"key":"2026052108402888000_13.8.e011761.139","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0734"},{"key":"2026052108402888000_13.8.e011761.140","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.156"},{"key":"2026052108402888000_13.8.e011761.141","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1"},{"key":"2026052108402888000_13.8.e011761.142","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.09.011"},{"key":"2026052108402888000_13.8.e011761.143","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-025-09212-7","article-title":"Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery","volume":"644","author":"Chen","year":"2025","journal-title":"Nature New Biol"},{"key":"2026052108402888000_13.8.e011761.144","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.cell.2025.02.035","article-title":"Engineering sonogenetic EchoBack-CAR T cells","volume":"188","author":"Liu","year":"2025","journal-title":"Cell"},{"key":"2026052108402888000_13.8.e011761.145","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.7.2541"},{"key":"2026052108402888000_13.8.e011761.146","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.3329"},{"key":"2026052108402888000_13.8.e011761.147","doi-asserted-by":"crossref","unstructured":"Svoboda J , Landsburg DJ , Nasta SD , et al . Safety and Efficacy of Armored huCART19-IL18 in Patients with Relapsed\/Refractory Lymphomas That Progressed after Anti-CD19 CAR T Cells. American Society of Clinical Oncology, 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.7004"},{"key":"2026052108402888000_13.8.e011761.148","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1"},{"key":"2026052108402888000_13.8.e011761.149","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314390"},{"key":"2026052108402888000_13.8.e011761.150","doi-asserted-by":"crossref","unstructured":"Stefanidis E , Semilietof A , Pujol J , et al . Combination of ny-eso-1-tcr-t-cells coengineered to secrete sirp\u03b1 decoys with anti-tumor antibodies to augment macrophage phagocytosis. bioRxiv [Preprint] 2023. doi:10.1101\/2023.06.27.546523","DOI":"10.1101\/2023.06.27.546523"},{"key":"2026052108402888000_13.8.e011761.151","doi-asserted-by":"crossref","unstructured":"Jia Q , Peng L , Chen G , et al . TCR-T Cells Armored with Immune Checkpoint Blockade in EBV-Positive Nasopharyngeal Carcinoma: The First-in-Human Phase 1\/2 Trial. American Society of Clinical Oncology, 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.6047"},{"key":"2026052108402888000_13.8.e011761.152","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607"},{"key":"2026052108402888000_13.8.e011761.153","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026052108402888000_13.8.e011761.154","doi-asserted-by":"crossref","unstructured":"Huang R , Wen Q , Zhang X . CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022. J Hematol Oncol 2023;16. doi:10.1186\/s13045-023-01435-3","DOI":"10.1186\/s13045-023-01435-3"},{"key":"2026052108402888000_13.8.e011761.155","doi-asserted-by":"crossref","unstructured":"Zhang L , Meng Y , Feng X , et al . CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomark Res 2022;10. doi:10.1186\/s40364-022-00364-6","DOI":"10.1186\/s40364-022-00364-6"},{"key":"2026052108402888000_13.8.e011761.156","doi-asserted-by":"crossref","unstructured":"Caruso S , De Angelis B , Del Bufalo F , et al . Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J Hematol Oncol 2022;15. doi:10.1186\/s13045-022-01376-3","DOI":"10.1186\/s13045-022-01376-3"},{"key":"2026052108402888000_13.8.e011761.157","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(01)02060-9"},{"key":"2026052108402888000_13.8.e011761.158","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.107022"},{"key":"2026052108402888000_13.8.e011761.159","doi-asserted-by":"crossref","first-page":"1211687","DOI":"10.3389\/fbioe.2023.1211687","article-title":"Emerging advances in nanobiomaterials-assisted chimeric antigen receptor (CAR)-macrophages for tumor immunotherapy","volume":"11","author":"Zhang","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"2026052108402888000_13.8.e011761.160","doi-asserted-by":"crossref","unstructured":"Page A , Hubert J , Fusil F , et al . Exploiting B cell transfer for cancer therapy: engineered B cells to eradicate tumors. Int J Mol Sci 2021;22. doi:10.3390\/ijms22189991","DOI":"10.3390\/ijms22189991"},{"key":"2026052108402888000_13.8.e011761.161","doi-asserted-by":"crossref","unstructured":"Smith AS , Knochelmann HM , Wyatt MM , et al . B cells imprint adoptively transferred CD8 + T cells with enhanced tumor immunity. J Immunother Cancer 2022;10. doi:10.1136\/jitc-2021-003078","DOI":"10.1136\/jitc-2021-003078"},{"key":"2026052108402888000_13.8.e011761.162","doi-asserted-by":"crossref","unstructured":"Ruffin AT , Cillo AR , Tabib T , et al . B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma. Nat Commun 2021;12. doi:10.1038\/s41467-021-23355-x","DOI":"10.1038\/s41467-021-23355-x"},{"key":"2026052108402888000_13.8.e011761.163","doi-asserted-by":"crossref","unstructured":"Cole AC , Knochelmann HM , Wyatt MM , et al . Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity. Cancer Cell 2025. doi:10.1016\/j.ccell.2025.07.001","DOI":"10.1016\/j.ccell.2025.07.001"},{"key":"2026052108402888000_13.8.e011761.164","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01659-y"},{"key":"2026052108402888000_13.8.e011761.165","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41419-024-06616-7","article-title":"Advances in engineered macrophages: a new frontier in cancer immunotherapy","volume":"15","author":"Yang","year":"2024","journal-title":"Cell Death Dis"},{"key":"2026052108402888000_13.8.e011761.166","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.97"},{"key":"2026052108402888000_13.8.e011761.167","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar7112"},{"key":"2026052108402888000_13.8.e011761.168","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/d41586-025-01570-6","article-title":"Cancer-fighting immune cells could soon be engineered inside our bodies","volume":"641","author":"Willyard","year":"2025","journal-title":"Nature New Biol"},{"key":"2026052108402888000_13.8.e011761.169","doi-asserted-by":"crossref","unstructured":"Pol J , Kroemer G , Galluzzi L . First Oncolytic Virus Approved for Melanoma Immunotherapy. Taylor & Francis, 2016.:e1115641.","DOI":"10.1080\/2162402X.2015.1115641"},{"key":"2026052108402888000_13.8.e011761.170","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj111"},{"key":"2026052108402888000_13.8.e011761.171","unstructured":"DELYTACT oncolytic virus g47\u2206 approved in japan for treatment of patients with malignant glioma. [press release]. 2021."},{"key":"2026052108402888000_13.8.e011761.172","doi-asserted-by":"publisher","DOI":"10.1089\/10430340150218396"},{"key":"2026052108402888000_13.8.e011761.173","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2012.14"},{"key":"2026052108402888000_13.8.e011761.174","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200106000-00012"},{"key":"2026052108402888000_13.8.e011761.175","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.040557897"},{"key":"2026052108402888000_13.8.e011761.176","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2001.0448"},{"key":"2026052108402888000_13.8.e011761.177","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/BF01665964","article-title":"Effect of virus-modified tumor cell extracts, autologous mononuclear cell infusions and interleukin-2 on oncolytic activity of effector cells of patients with advanced ovarian cancer","volume":"30","author":"Furukawa","year":"1989","journal-title":"Cancer Immunol Immunother"},{"key":"2026052108402888000_13.8.e011761.178","doi-asserted-by":"crossref","unstructured":"Zamarin D , Holmgaard RB , Subudhi SK , et al . Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014;6. doi:10.1126\/scitranslmed.3008095","DOI":"10.1126\/scitranslmed.3008095"},{"key":"2026052108402888000_13.8.e011761.179","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1638"},{"key":"2026052108402888000_13.8.e011761.180","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17425247.2019.1617269","article-title":"Achieving systemic delivery of oncolytic viruses","volume":"16","author":"Hill","year":"2019","journal-title":"Expert Opin Drug Deliv"},{"key":"2026052108402888000_13.8.e011761.181","doi-asserted-by":"crossref","first-page":"213208","DOI":"10.1016\/j.bioadv.2022.213208","article-title":"Affilin-based retargeting of adenoviral vectors to the epidermal growth factor receptor","volume":"144","author":"Wienen","year":"2023","journal-title":"Biomater Adv"},{"key":"2026052108402888000_13.8.e011761.182","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4236\/jct.2021.126029","article-title":"CXCL12 retargeting of an oncolytic adenovirus vector to the chemokine CXCR4 and CXCR7 receptors in breast cancer","volume":"12","author":"O\u2019Bryan","year":"2021","journal-title":"J Cancer Ther"},{"key":"2026052108402888000_13.8.e011761.183","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/1873-3468.13731","article-title":"Retargeting adenoviruses for therapeutic applications and vaccines","volume":"594","author":"Barry","year":"2020","journal-title":"FEBS Lett"},{"key":"2026052108402888000_13.8.e011761.184","doi-asserted-by":"crossref","unstructured":"Khanduja S , Bloom SMK , Raman V , et al . Intracellular delivery of oncolytic viruses with engineered Salmonella causes viral replication and cell death. iScience 2024;27. doi:10.1016\/j.isci.2024.109813","DOI":"10.1016\/j.isci.2024.109813"},{"key":"2026052108402888000_13.8.e011761.185","first-page":"28","article-title":"Engineered bacteria launch and control an oncolytic virus","volume":"2023","author":"Singer","year":"2023","journal-title":"bioRxiv"},{"key":"2026052108402888000_13.8.e011761.186","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.283"},{"key":"2026052108402888000_13.8.e011761.187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OV.S66083","article-title":"Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances","volume":"2016","author":"Pandha","year":"2016","journal-title":"OV"},{"key":"2026052108402888000_13.8.e011761.188","doi-asserted-by":"crossref","unstructured":"O\u2019Cathail SM , Pokrovska TD , Maughan TS , et al . Combining oncolytic adenovirus with radiation-a paradigm for the future of radiosensitization. Front Oncol 2017;7. doi:10.3389\/fonc.2017.00153","DOI":"10.3389\/fonc.2017.00153"},{"key":"2026052108402888000_13.8.e011761.189","doi-asserted-by":"crossref","unstructured":"Lussier DM , Alspach E , Ward JP , et al . Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc Natl Acad Sci U S A 2021;118. doi:10.1073\/pnas.2102611118","DOI":"10.1073\/pnas.2102611118"},{"key":"2026052108402888000_13.8.e011761.190","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/agm2.12295","article-title":"Tumor neoantigens and tumor immunotherapies","volume":"7","author":"Jiani","year":"2024","journal-title":"Aging Med (Milton)"},{"key":"2026052108402888000_13.8.e011761.191","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701024"},{"key":"2026052108402888000_13.8.e011761.192","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0274"},{"key":"2026052108402888000_13.8.e011761.193","doi-asserted-by":"crossref","unstructured":"Butterfield LH . Dendritic cells in cancer immunotherapy clinical trials: are we making progress? Front Immunol 2013;4. doi:10.3389\/fimmu.2013.00454","DOI":"10.3389\/fimmu.2013.00454"},{"key":"2026052108402888000_13.8.e011761.194","doi-asserted-by":"crossref","unstructured":"Ung T , Rutledge NS , Weiss AM , et al . Cell-targeted vaccines: implications for adaptive immunity. Front Immunol 2023;14. doi:10.3389\/fimmu.2023.1221008","DOI":"10.3389\/fimmu.2023.1221008"},{"key":"2026052108402888000_13.8.e011761.195","doi-asserted-by":"crossref","unstructured":"Jin Q , Wang Z , Floudas CS , et al . Matching patients to clinical trials with large language models. Nat Commun 2024;15. doi:10.1038\/s41467-024-53081-z","DOI":"10.1038\/s41467-024-53081-z"},{"key":"2026052108402888000_13.8.e011761.196","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/s43018-024-00772-7","article-title":"LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features","volume":"5","author":"Chang","year":"2024","journal-title":"Nat Cancer"},{"key":"2026052108402888000_13.8.e011761.197","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01960-7"},{"key":"2026052108402888000_13.8.e011761.198","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41698-023-00473-x","article-title":"Radiological artificial intelligence - predicting personalized immunotherapy outcomes in lung cancer","volume":"7","author":"Roisman","year":"2023","journal-title":"npj Precis Onc"},{"key":"2026052108402888000_13.8.e011761.199","doi-asserted-by":"crossref","unstructured":"Alilou M , Khorrami M , Prasanna P , et al . A tumor vasculature-based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors. Sci Adv 2022;8. doi:10.1126\/sciadv.abq4609","DOI":"10.1126\/sciadv.abq4609"},{"key":"2026052108402888000_13.8.e011761.200","doi-asserted-by":"crossref","unstructured":"Kong J , Ha D , Lee J , et al . Network-based machine learning approach to predict immunotherapy response in cancer patients. Nat Commun 2022;13. doi:10.1038\/s41467-022-31535-6","DOI":"10.1038\/s41467-022-31535-6"},{"key":"2026052108402888000_13.8.e011761.201","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0641"},{"key":"2026052108402888000_13.8.e011761.202","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1158\/2767-9764.CRC-22-0339","article-title":"Probabilistic mixture models improve calibration of panel-derived tumor mutational burden in the context of both tumor-normal and tumor-only sequencing","volume":"3","author":"Anaya","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2026052108402888000_13.8.e011761.203","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01684-0"},{"key":"2026052108402888000_13.8.e011761.204","doi-asserted-by":"crossref","unstructured":"Fischer DS , Wu Y , Schubert B , et al . Predicting antigen specificity of single T cells based on tcr cdr 3 regions. Mol Syst Biol 2020;16. doi:10.15252\/msb.20199416","DOI":"10.15252\/msb.20199416"},{"key":"2026052108402888000_13.8.e011761.205","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s42256-021-00383-2","article-title":"Deep learning-based prediction of the T cell receptor\u2013antigen binding specificity","volume":"3","author":"Lu","year":"2021","journal-title":"Nat Mach Intell"},{"key":"2026052108402888000_13.8.e011761.206","doi-asserted-by":"crossref","unstructured":"Sidhom J-W , Oliveira G , Ross-MacDonald P , et al . Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy. Sci Adv 2022;8. doi:10.1126\/sciadv.abq5089","DOI":"10.1126\/sciadv.abq5089"},{"key":"2026052108402888000_13.8.e011761.207","doi-asserted-by":"crossref","unstructured":"Montemurro A , Schuster V , Povlsen HR , et al . NetTCR-2.0 enables accurate prediction of TCR-peptide binding by using paired TCR\u03b1 and \u03b2 sequence data. Commun Biol 2021;4. doi:10.1038\/s42003-021-02610-3","DOI":"10.1038\/s42003-021-02610-3"},{"key":"2026052108402888000_13.8.e011761.208","doi-asserted-by":"crossref","unstructured":"Sidhom J-W , Larman HB , Pardoll DM , et al . DeepTCR is a deep learning framework for revealing sequence concepts within T-cell repertoires. Nat Commun 2021;12. doi:10.1038\/s41467-021-21879-w","DOI":"10.1038\/s41467-021-21879-w"},{"key":"2026052108402888000_13.8.e011761.209","doi-asserted-by":"crossref","unstructured":"Jiang Y , Huo M , Cheng Li S . TEINet: a deep learning framework for prediction of TCR\u2013epitope binding specificity. Brief Bioinformatics 2023;24. doi:10.1093\/bib\/bbad086","DOI":"10.1093\/bib\/bbad086"},{"key":"2026052108402888000_13.8.e011761.210","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41587-024-02232-0","article-title":"Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms","volume":"43","author":"P\u00e9tremand","year":"2025","journal-title":"Nat Biotechnol"},{"key":"2026052108402888000_13.8.e011761.211","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-024-00936-1"},{"key":"2026052108402888000_13.8.e011761.212","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq0225"},{"key":"2026052108402888000_13.8.e011761.213","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cels.2020.08.002","article-title":"Discriminatory power of combinatorial antigen recognition in cancer T cell therapies","volume":"11","author":"Dannenfelser","year":"2020","journal-title":"Cell Syst"},{"key":"2026052108402888000_13.8.e011761.214","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01763-2"},{"key":"2026052108402888000_13.8.e011761.215","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk8946"},{"key":"2026052108402888000_13.8.e011761.216","doi-asserted-by":"crossref","unstructured":"He C , Mansilla-Soto J , Khanra N , et al . CD19 CAR antigen engagement mechanisms and affinity tuning. Sci Immunol 2023;8. doi:10.1126\/sciimmunol.adf1426","DOI":"10.1126\/sciimmunol.adf1426"},{"key":"2026052108402888000_13.8.e011761.217","doi-asserted-by":"crossref","unstructured":"Zoine JT , Immadisetty K , Ibanez-Vega J , et al . Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity. Cell Rep Med 2024;5. doi:10.1016\/j.xcrm.2024.101422","DOI":"10.1016\/j.xcrm.2024.101422"},{"key":"2026052108402888000_13.8.e011761.218","doi-asserted-by":"crossref","first-page":"1250508","DOI":"10.3389\/fmmed.2023.1250508","article-title":"Elaborating the potential of Artificial Intelligence in automated CAR-T cell manufacturing","volume":"3","author":"B\u00e4ckel","year":"2023","journal-title":"Front Mol Med"},{"key":"2026052108402888000_13.8.e011761.219","doi-asserted-by":"crossref","unstructured":"Hort S , Herbst L , B\u00e4ckel N , et al . Toward rapid, widely available autologous CAR-T cell therapy - artificial intelligence and automation enabling the smart manufacturing hospital. Front Med (Lausanne) 2022;9. doi:10.3389\/fmed.2022.913287","DOI":"10.3389\/fmed.2022.913287"},{"key":"2026052108402888000_13.8.e011761.220","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01038-6"},{"key":"2026052108402888000_13.8.e011761.221","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1200\/OP.23.00435","article-title":"State of cancer care in america: achieving cancer health equity among sexual and gender minority communities","volume":"19","author":"Kamen","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"2026052108402888000_13.8.e011761.222","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-20-0007"},{"key":"2026052108402888000_13.8.e011761.223","unstructured":"Maxwell A . Plans and enrollment often fell short for underrepresented groups in a sample of nih-funded clinical trials: department of health and human services. 2024. Available: https:\/\/oig.hhs.gov\/documents\/evaluation\/9900\/OEI-01-21-00320.pdf"},{"key":"2026052108402888000_13.8.e011761.224","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1016\/j.pec.2022.04.014","article-title":"Engaging with ethnic minority consumers to improve safety in cancer services: a national stakeholder analysis","volume":"105","author":"Joseph","year":"2022","journal-title":"Patient Educ Couns"},{"key":"2026052108402888000_13.8.e011761.225","unstructured":"Consortium GP . A global reference for human genetic variation. Nature New Biol 2015;526."},{"key":"2026052108402888000_13.8.e011761.226","doi-asserted-by":"crossref","unstructured":"Gomez F , Hirbo J , Tishkoff SA . Genetic variation and adaptation in Africa: implications for human evolution and disease. Cold Spring Harb Perspect Biol 2014;6. doi:10.1101\/cshperspect.a008524","DOI":"10.1101\/cshperspect.a008524"},{"key":"2026052108402888000_13.8.e011761.227","doi-asserted-by":"crossref","first-page":"e1088","DOI":"10.1016\/S2214-109X(22)00243-1","article-title":"The African Medicines Agency: the key to unlocking clinical research in Africa","volume":"10","author":"Hwenda","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2026052108402888000_13.8.e011761.228","doi-asserted-by":"crossref","first-page":"168","DOI":"10.36401\/JIPO-23-42","article-title":"Phase 1 clinical trials: challenges and opportunities in Latin America","volume":"7","author":"Nardo","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"2026052108402888000_13.8.e011761.229","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1089\/jwh.2020.8674","article-title":"Evaluating the National Institutes of health\u2019s sex as a biological variable policy: conflicting accounts from the front lines of animal research","volume":"30","author":"Waltz","year":"2021","journal-title":"J Womens Health (Larchmt)"},{"key":"2026052108402888000_13.8.e011761.230","doi-asserted-by":"crossref","unstructured":"Choe JH , Watchmaker PB , Simic MS , et al . SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med 2021;13. doi:10.1126\/scitranslmed.abe7378","DOI":"10.1126\/scitranslmed.abe7378"},{"key":"2026052108402888000_13.8.e011761.231","doi-asserted-by":"crossref","unstructured":"Yang Y , Vedvyas Y , Alcaina Y , et al . Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity. JCI Insight 2024;9. doi:10.1172\/jci.insight.186268","DOI":"10.1172\/jci.insight.186268"},{"key":"2026052108402888000_13.8.e011761.232","doi-asserted-by":"crossref","unstructured":"Wang H , Wu Z , Cui D , et al . Triple knockdown of CD11a, CD49d, and PSGL1 in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice. Sci Transl Med 2025;17. doi:10.1126\/scitranslmed.adl6432","DOI":"10.1126\/scitranslmed.adl6432"},{"key":"2026052108402888000_13.8.e011761.233","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114145"},{"key":"2026052108402888000_13.8.e011761.234","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1855"},{"key":"2026052108402888000_13.8.e011761.235","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.06.008"},{"key":"2026052108402888000_13.8.e011761.236","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.08.007"},{"key":"2026052108402888000_13.8.e011761.237","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.crimmu.2022.05.003","article-title":"Clinically approved combination immunotherapy: Current status, limitations, and future perspective","volume":"3","author":"Lu","year":"2022","journal-title":"Curr Res Immunol"},{"key":"2026052108402888000_13.8.e011761.238","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02039-z"},{"key":"2026052108402888000_13.8.e011761.239","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300709"},{"key":"2026052108402888000_13.8.e011761.240","doi-asserted-by":"crossref","unstructured":"Qu J , Wang Y , Xiong C , et al . In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy. Nat Commun 2024;15. doi:10.1038\/s41467-024-54292-0","DOI":"10.1038\/s41467-024-54292-0"},{"key":"2026052108402888000_13.8.e011761.241","doi-asserted-by":"crossref","unstructured":"Mai D , June CH , Sheppard NC . In vivo gene immunotherapy for cancer. Sci Transl Med 2022;14. doi:10.1126\/scitranslmed.abo3603","DOI":"10.1126\/scitranslmed.abo3603"},{"key":"2026052108402888000_13.8.e011761.242","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2018.06.002"},{"key":"2026052108402888000_13.8.e011761.243","doi-asserted-by":"crossref","unstructured":"Kareff SA , Han S , Haaland B , et al . International cost-effectiveness analysis of durvalumab in stage III non-small cell lung cancer. JAMA Netw Open 2024;7. doi:10.1001\/jamanetworkopen.2024.13938","DOI":"10.1001\/jamanetworkopen.2024.13938"},{"key":"2026052108402888000_13.8.e011761.244","doi-asserted-by":"crossref","unstructured":"Schaft N , D\u00f6rrie J , Schuler G , et al . The future of affordable cancer immunotherapy. Front Immunol 2023;14. doi:10.3389\/fimmu.2023.1248867","DOI":"10.3389\/fimmu.2023.1248867"},{"key":"2026052108402888000_13.8.e011761.245","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1200\/JCO.22.01711","article-title":"Cost savings and increased access with ultra-low-dose immunotherapy","volume":"41","author":"Mitchell","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026052108402888000_13.8.e011761.246","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.cels.2024.08.004","article-title":"Discovery of therapeutic targets in cancer using chromatin accessibility and transcriptomic data","volume":"15","author":"Forbes","year":"2024","journal-title":"Cell Syst"},{"key":"2026052108402888000_13.8.e011761.247","doi-asserted-by":"crossref","unstructured":"Abd El-Hafeez T , Shams MY , Elshaier Y , et al . Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs. Sci Rep 2024;14. doi:10.1038\/s41598-024-52814-w","DOI":"10.1038\/s41598-024-52814-w"},{"key":"2026052108402888000_13.8.e011761.248","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s43018-024-00756-7","article-title":"PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors","volume":"5","author":"Sinha","year":"2024","journal-title":"Nat Cancer"},{"key":"2026052108402888000_13.8.e011761.249","doi-asserted-by":"crossref","unstructured":"Litzow M , Sun Z , Mattison R , et al . S115: consolidation with blinatumomab improves overall and relapse-free survival in patients with newly diagnosed B-cell acute lymphoblastic leukemia: impact of age and mrd level in ecog-acrin e1910. Hemasphere 2023;7. doi:10.1097\/01.HS9.0000967372.19440.62","DOI":"10.1097\/01.HS9.0000967372.19440.62"},{"key":"2026052108402888000_13.8.e011761.250","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0071"},{"key":"2026052108402888000_13.8.e011761.251","doi-asserted-by":"crossref","unstructured":"Burton J , Siller-Farf\u00e1n JA , Pettmann J , et al . Inefficient exploitation of accessory receptors reduces the sensitivity of chimeric antigen receptors. Proc Natl Acad Sci USA 2023;120. doi:10.1073\/pnas.2216352120","DOI":"10.1073\/pnas.2216352120"},{"key":"2026052108402888000_13.8.e011761.252","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/1078-0432.CCR-24-1552","article-title":"A first-in-human study of cinrebafusp alfa, a HER2\/4-1BB bispecific molecule, in patients with HER2-positive advanced solid malignancies","volume":"31","author":"Piha-Paul","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026052108402888000_13.8.e011761.253","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026052108402888000_13.8.e011761.254","doi-asserted-by":"crossref","unstructured":"Sridhar S , Castro PG , Aerts J , et al . 655 Acasunlimab in combination with pembrolizumab reinvigorates anti-tumor immunity in patients with previously treated metastatic non-small cell lung cancer (NSCLC). BMJ Specialist J 2024. doi:10.1136\/jitc-2024-SITC2024.0655","DOI":"10.1136\/jitc-2024-SITC2024.0655"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-011761","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:41:22Z","timestamp":1779378082000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-011761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":254,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,25]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/jitc-2025-011761"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-011761","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}